

# **Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021**

<https://marketpublishers.com/r/A89F8EC233FEN.html>

Date: September 2016

Pages: 167

Price: US\$ 5,650.00 (Single User License)

ID: A89F8EC233FEN

## **Abstracts**

The global antinuclear antibody (ANA) testing market is expected to reach USD 1,476.1 million by 2021 from USD 823.5 million in 2016, at a CAGR of 12.4%. The global ANA testing market is segmented based on products, diseases, techniques, end users, and regions. The assay kits & reagents segment is expected to register the highest growth rate in the ANA testing market, by product, during the forecast period. The high growth in this segment is attributed to the growing number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide.

Based on end users, the ANA testing market is segmented into clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share of the market in 2016. Increasing prevalence of autoimmune diseases, coupled with the fact that most diagnostic tests are performed in hospitals or hospital-attached laboratories, will be the major factors driving the growth of this market.

North America is the largest regional segment in the global ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the rising geriatric population and the growing number of people covered under medical insurance in the U.S.

In addition to comprehensive geographic and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. The company profiles in this report

comprise the product portfolios, developments, and strategies adopted by players to maintain and increase their shares in the market. The abovementioned market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the ANA testing market.

The major players in this market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).

#### Objectives of the Study:

To define, describe, and forecast the global antinuclear antibody testing market on the basis of product, technique, disease, and end user

To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, and trends)

To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)

To strategically analyze the market structure and profile the key players operating in the global ANA testing market and comprehensively analyze their core competencies

To track and analyze competitive developments such as new product launches, agreements, expansions, and acquisitions in the global ANA testing market

#### Target Audience for this Report:

ANA Testing Instrument Manufacturers and Suppliers

Clinical Laboratories

Hospitals

Pharmaceutical and Biotechnology Companies

Academic Research Institutes Related to Antinuclear Antibody Testing

## Contents

### **1 INTRODUCTION**

- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
  - 1.3.1 MARKETS COVERED
  - 1.3.2 YEARS CONSIDERED FOR THE STUDY
- 1.4 CURRENCY
- 1.5 LIMITATIONS
- 1.6 STAKEHOLDERS

### **2 RESEARCH METHODOLOGY**

- 2.1 SECONDARY DATA
  - 2.1.1 KEY DATA FROM SECONDARY SOURCES
- 2.2 PRIMARY DATA
  - 2.2.1 KEY DATA FROM PRIMARY SOURCES
- 2.3 MARKET SIZE ESTIMATION
  - 2.3.1 BOTTOM-UP APPROACH
  - 2.3.2 TOP-DOWN APPROACH
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 ASSUMPTIONS FOR THE STUDY

### **3 EXECUTIVE SUMMARY**

- 3.1 INTRODUCTION
- 3.2 CURRENT SCENARIO
- 3.3 FUTURE OUTLOOK
- 3.4 CONCLUSION

### **4 PREMIUM INSIGHTS**

- 4.1 ANA TESTING MARKET OVERVIEW
- 4.2 LIFE CYCLE ANALYSIS, BY REGION

### **5 MARKET OVERVIEW**

## 5.1 INTRODUCTION

## 5.2 MARKET SEGMENTATION

## 5.3 MARKET DYNAMICS

### 5.3.1 DRIVERS

5.3.1.1 High Incidence of Autoimmune Diseases

5.3.1.2 Increasing Population and Growth in Healthcare Expenditure

5.3.1.3 Growth in the Number of Individuals Covered Under Medical Insurance

### 5.3.2 RESTRAINTS

5.3.2.1 Stringent Regulations for the Approval of Medical Devices

5.3.2.2 Implementation of Excise Duty on Medical Devices in the U.S.

5.3.2.3 Requirement of Significant Capital to Purchase High-cost Equipment

### 5.3.3 OPPORTUNITIES

5.3.3.1 Laboratory Automation

5.3.3.2 Emerging Markets in Asia Present High-growth Opportunities

### 5.3.4 TREND

5.3.4.1 Reagent Rental Agreements

## 6 ANTINUCLEAR ANTIBODY TESTING MARKET, BY PRODUCT

### 6.1 INTRODUCTION

### 6.2 REAGENTS & ASSAY KITS

### 6.3 SYSTEMS

### 6.4 SOFTWARE & SERVICES

## 7 ANTINUCLEAR ANTIBODY TESTING MARKET, BY TECHNIQUE

### 7.1 INTRODUCTION

### 7.2 ELISA

### 7.3 IMMUNOFLUORESCENCE ASSAY

### 7.4 MULTIPLEX ASSAY

## 8 ANTINUCLEAR ANTIBODY TESTING MARKET, BY DISEASE

### 8.1 INTRODUCTION

### 8.2 RHEUMATOID ARTHRITIS

### 8.3 SYSTEMIC LUPUS ERYTHEMATOSUS

### 8.4 SJOGREN'S SYNDROME

### 8.5 SCLERODERMA

### 8.6 OTHER DISEASES

## **9 ANTINUCLEAR ANTIBODY TESTING MARKET, BY END USER**

### 9.1 INTRODUCTION

### 9.2 HOSPITALS

#### 9.2.1 SMALL HOSPITALS

#### 9.2.2 MID-SIZED HOSPITALS

#### 9.2.3 LARGE HOSPITALS

### 9.3 CLINICAL LABORATORIES

### 9.4 PHYSICIAN OFFICE LABORATORIES

### 9.5 OTHER END USERS

## **10 GEOGRAPHIC ANALYSIS**

### 10.1 INTRODUCTION

### 10.2 NORTH AMERICA

#### 10.2.1 U.S.

#### 10.2.2 CANADA

### 10.3 EUROPE

### 10.4 ASIA

#### 10.4.1 CHINA

#### 10.4.2 JAPAN

#### 10.4.3 INDIA

#### 10.4.4 REST OF THE ASIA (ROA)

### 10.5 REST OF THE WORLD

## **11 COMPETITIVE LANDSCAPE**

### 11.1 INTRODUCTION

### 11.2 STRATEGIC OVERVIEW

### 11.3 MARKET SHARE ANALYSIS

### 11.4 COMPETITIVE SITUATION AND TRENDS

#### 11.4.1 ACQUISITIONS

#### 11.4.2 AGREEMENTS

#### 11.4.3 NEW PRODUCT LAUNCHES

#### 11.4.4 EXPANSIONS

#### 11.4.5 OTHER DEVELOPMENTS

## **12 COMPANY PROFILES**

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)\*

12.1 INTRODUCTION

12.2 THERMO FISHER SCIENTIFIC, INC.

12.3 ALERE INC.

12.4 BIO-RAD LABORATORIES, INC.

12.5 TRINITY BIOTECH PLC

12.6 ERBA DIAGNOSTICS, INC.

12.7 ANTIBODIES INC.

12.8 EUROIMMUN AG

12.9 IMMUNO CONCEPTS

12.10 INOVA DIAGNOSTICS

12.11 ZEUS SCIENTIFIC, INC.

\*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

## **13 APPENDIX**

13.1 INSIGHTS OF INDUSTRY EXPERTS

13.2 DISCUSSION GUIDE

13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE

13.5 AVAILABLE CUSTOMIZATIONS

13.6 RELATED REPORTS

## List Of Tables

### LIST OF TABLES

Table 1 PREVALENCE DATA FOR AUTOIMMUNE DISEASES

Table 2 HIGH INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE MARKET GROWTH

Table 3 IMPLEMENTATION OF EXCISE DUTY ON MEDICAL DEVICES IN THE U.S. TO RESTRAIN MARKET GROWTH

Table 4 GROWING DEMAND FOR LAB AUTOMATION TO OFFER MAJOR GROWTH OPPORTUNITIES

Table 5 REAGENT RENTAL AGREEMENTS ARE AN IMPORTANT TREND IN THE ANA TESTING MARKET

Table 6 ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 7 ANA TESTING MARKET SIZE FOR REAGENTS & ASSAY KITS, BY REGION, 2014–2021 (USD MILLION)

Table 8 ANA TESTING MARKET SIZE FOR SYSTEMS, BY REGION, 2014–2021 (USD MILLION)

Table 9 ANA TESTING MARKET SIZE FOR SOFTWARE & SERVICES, BY REGION, 2014–2021 (USD MILLION)

Table 10 ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 11 ANA TESTING MARKET SIZE FOR ELISA, BY REGION, 2014–2021 (USD MILLION)

Table 12 ANA TESTING MARKET SIZE FOR IFA, BY REGION, 2014–2021 (USD MILLION)

Table 13 ANA TESTING MARKET SIZE FOR MULTIPLEX ASSAYS, BY REGION, 2014–2021 (USD MILLION)

Table 14 ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY DISEASE, 2014–2021 (USD MILLION)

Table 15 ANA TESTING MARKET SIZE FOR RHEUMATOID ARTHRITIS, BY REGION, 2014–2021 (USD MILLION)

Table 16 ANA TESTING MARKET SIZE FOR SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2014–2021 (USD MILLION)

Table 17 ANA TESTING MARKET SIZE FOR SJ?GREN'S SYNDROME, BY REGION, 2014–2021 (USD MILLION)

Table 18 ANA TESTING MARKET SIZE FOR SCLERODERMA, BY REGION, 2014–2021 (USD MILLION)



Table 19 ANA TESTING MARKET SIZE FOR OTHER DISEASES, BY REGION, 2014–2021 (USD MILLION)

Table 20 ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 21 GLOBAL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE FOR HOSPITALS, BY TYPE, 2014–2021 (USD MILLION)

Table 22 ANA TESTING MARKET SIZE FOR HOSPITALS, BY REGION, 2014–2021 (USD MILLION)

Table 23 ANA TESTING MARKET SIZE FOR SMALL HOSPITALS, BY REGION, 2014–2021 (USD MILLION)

Table 24 ANA TESTING MARKET SIZE FOR MID-SIZED HOSPITALS, BY REGION, 2014–2021 (USD MILLION)

Table 25 ANA TESTING MARKET SIZE FOR LARGE HOSPITALS, BY REGION, 2014–2021 (USD MILLION)

Table 26 ANA TESTING MARKET SIZE FOR CLINICAL LABORATORIES, BY REGION, 2014–2021 (USD MILLION)

Table 27 ANA TESTING MARKET SIZE FOR PHYSICIAN OFFICE LABORATORIES, BY REGION, 2014–2021 (USD MILLION)

Table 28 ANA TESTING MARKET SIZE FOR OTHER END USERS, BY REGION, 2014–2021 (USD MILLION)

Table 29 ANA TESTING MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)

Table 30 NORTH AMERICA: ANA TESTING MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 31 NORTH AMERICA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 32 NORTH AMERICA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 33 NORTH AMERICA: ANA TESTING MARKET SIZE, BY DISEASE, 2014–2021 (USD MILLION)

Table 34 NORTH AMERICA: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 35 U.S.: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 36 U.S.: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 37 U.S.: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 38 CANADA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 39 CANADA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 40 CANADA: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 41 EUROPE: ANA TESTING MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 42 EUROPE: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 43 EUROPE: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 44 EUROPE: ANA TESTING MARKET SIZE, BY DISEASE, 2014–2021 (USD MILLION)

Table 45 EUROPE: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 46 ASIA: ANA TESTING MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 47 ASIA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 48 ASIA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 49 ASIA: ANA TESTING MARKET SIZE, BY DISEASE, 2014–2021 (USD MILLION)

Table 50 ASIA: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 51 CHINA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 52 CHINA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 53 CHINA: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 54 JAPAN: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 55 JAPAN: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 56 JAPAN: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 57 INDIA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 58 INDIA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD

MILLION)

Table 59 INDIA: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 60 ROA: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 61 ROA: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 62 ROA: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 63 ROW: ANA TESTING MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION)

Table 64 ROW: ANA TESTING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)

Table 65 ROW: ANA TESTING MARKET SIZE, BY TECHNIQUE, 2014–2021 (USD MILLION)

Table 66 ROW: ANA TESTING MARKET SIZE, BY DISEASE, 2014–2021 (USD MILLION)

Table 67 ROW: ANA TESTING MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)

Table 68 GROWTH STRATEGY MATRIX, 2013–2016

Table 69 ACQUISITIONS, 2013–2016

Table 70 AGREEMENTS, 2013–2016

Table 71 NEW PRODUCT LAUNCHES, 2013–2016

Table 72 EXPANSIONS, 2013–2016

Table 73 OTHER DEVELOPMENTS, 2013–2016

## List Of Figures

### LIST OF FIGURES

Figure 1 MARKET SEGMENTATION

Figure 2 RESEARCH DESIGN

Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

Figure 4 ANA TESTING MARKET: BOTTOM-UP APPROACH

Figure 5 ANA TESTING MARKET: TOP-DOWN APPROACH

Figure 6 DATA TRIANGULATION METHODOLOGY

Figure 7 GLOBAL ANA TESTING MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION)

Figure 8 GLOBAL ANA TESTING MARKET SIZE, BY TECHNIQUE, 2016 VS 2021 (USD MILLION)

Figure 9 GLOBAL ANA TESTING MARKET SIZE, BY DISEASE TYPE, 2016 VS 2021 (USD MILLION)

Figure 10 GLOBAL ANA TESTING MARKET SIZE, BY END USER, 2016 VS 2021 (USD MILLION)

Figure 11 GLOBAL ANA TESTING MARKET SIZE, BY REGION, 2016 VS 2021 (USD MILLION)

Figure 12 GLOBAL ANA TESTING MARKET TO WITNESS MODERATE GROWTH DURING THE FORECAST PERIOD

Figure 13 HOSPITALS SEGMENT TO DOMINATE THE GLOBAL ANA TESTING MARKET IN 2016

Figure 14 ASIA PROJECTED TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD (2016-2021)

Figure 15 ASIAN MARKET SHOWCASES LUCRATIVE GROWTH OPPORTUNITIES

Figure 16 ANTINUCLEAR ANTIBODY TESTING MARKET SEGMENTATION

Figure 17 ANA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & TRENDS

Figure 18 GLOBAL POPULATION DATA (2010–2015), IN BILLION

Figure 19 GLOBAL HEALTHCARE AND PUBLIC HEALTHCARE SPENDING, 2010-2015

Figure 20 GROWTH IN HEALTHCARE EXPENDITURE, BY REGION

Figure 21 REAGENTS & ASSAY KITS TO FORM THE LARGEST PRODUCT SEGMENT IN 2016

Figure 22 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR REAGENTS & ASSAY KITS IN 2016

Figure 23 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SYSTEMS IN 2016

Figure 24 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SOFTWARE & SERVICES IN 2016

Figure 25 ELISA TECHNIQUE TO DOMINATE THE ANTINUCLEAR ANTIBODY TESTING MARKET IN 2016

Figure 26 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR ELISA IN 2016

Figure 27 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR IMMUNOFLUORESCENCE ASSAY IN 2016

Figure 28 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR MULTIPLEX ASSAYS IN 2016

Figure 29 RHEUMATOID ARTHRITIS TO DOMINATE THE ANTINUCLEAR ANTIBODY TESTING MARKET, BY DISEASE, IN 2016

Figure 30 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR RHEUMATOID ARTHRITIS IN 2016

Figure 31 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN 2016

Figure 32 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SJ?GREN'S SYNDROME IN 2016

Figure 33 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SCLERODERMA IN 2016

Figure 34 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR OTHER DISEASES IN 2016

Figure 35 ANTINUCLEAR ANTIBODY TESTING MARKET SIZE, BY END USER, 2016 (USD MILLION)

Figure 36 GLOBAL ANTINUCLEAR ANTIBODY TESTING MARKET SIZE FOR HOSPITALS, BY TYPE, 2016 (USD MILLION)

Figure 37 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR HOSPITALS IN 2016

Figure 38 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR SMALL HOSPITALS IN 2016

Figure 39 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR MID-SIZED HOSPITALS IN 2016

Figure 40 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR LARGE HOSPITALS IN 2016

Figure 41 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR CLINICAL LABORATORIES IN 2016

Figure 42 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR

PHYSICIAN OFFICE LABORATORIES IN 2016

Figure 43 NORTH AMERICA TO DOMINATE THE ANA TESTING MARKET FOR OTHER END USERS IN 2016

Figure 44 GLOBAL ECONOMIC INDICATORS (2005–2014)

Figure 45 GEOGRAPHIC SNAPSHOT OF THE ANTINUCLEAR ANTIBODY TESTING MARKET

Figure 46 ANA TESTING MARKET, BY REGION (MARKET SIZE AND GROWTH RATE)

Figure 47 NORTH AMERICA: ECONOMIC INDICATORS (2005–2014)

Figure 48 NORTH AMERICA: ANTINUCLEAR ANTIBODY MARKET SNAPSHOT, 2016

Figure 49 NORTH AMERICA: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)

Figure 50 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN NORTH AMERICA IN 2016

Figure 51 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 52 RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 53 HOSPITALS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKETS IN 2016

Figure 54 U.S.: ECONOMIC INDICATORS (2005–2014)

Figure 55 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016

Figure 56 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 57 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 58 CANADA: ECONOMIC INDICATORS (2005–2014)

Figure 59 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016

Figure 60 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 61 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 62 EUROPE: ECONOMIC INDICATORS (2005–2014)

Figure 63 EUROPE: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)

Figure 64 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 65 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 66 RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 67 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 68 ASIA: ECONOMIC INDICATORS (2005–2014)

Figure 69 ASIA: ANTINUCLEAR ANTIBODY MARKET SNAPSHOT, 2016

Figure 70 ASIA: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)

Figure 71 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 72 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 73 RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 74 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 75 CHINA: ECONOMIC INDICATORS (2005–2014)

Figure 76 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016

Figure 77 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 78 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 79 JAPAN: ECONOMIC INDICATORS (2005–2014)

Figure 80 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016

Figure 81 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 82 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 83 INDIA: ECONOMIC INDICATORS (2005–2014)

Figure 84 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE IN 2016

Figure 85 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 86 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 87 REAGENTS & ASSAY KITS TO ACCOUNT FOR LARGEST SHARE IN 2016

Figure 88 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 89 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 90 ROW: ANA TESTING MARKET, BY COUNTRY (MARKET SIZE AND GROWTH RATE)

Figure 91 REAGENTS & ASSAY KITS TO ACCOUNT FOR THE LARGEST SHARE OF



THE ANA TESTING MARKET IN 2016

Figure 92 ELISA TECHNIQUE TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 93 RHEUMATOID ARTHRITIS TO ACCOUNT FOR THE LARGEST SHARE OF THE ANA TESTING MARKET IN 2016

Figure 94 HOSPITALS TO DOMINATE THE ANA TESTING MARKET IN 2016

Figure 95 NEW PRODUCT LAUNCHES, ACQUISITIONS, AND AGREEMENTS—KEY GROWTH STRATEGIES ADOPTED BY PLAYERS IN THE ANA TESTING MARKET

Figure 96 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014

Figure 97 FINANCIAL PERFORMANCES OF THE LEADING MARKET PLAYERS

Figure 98 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT

Figure 99 ALERE INC.: COMPANY SNAPSHOT

Figure 100 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT

Figure 101 TRINITY BIOTECH PLC: COMPANY SNAPSHOT

Figure 102 ERBA DIAGNOSTICS, INC.: COMPANY SNAPSHOT



## I would like to order

Product name: Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021

Product link: <https://marketpublishers.com/r/A89F8EC233FEN.html>

Price: US\$ 5,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A89F8EC233FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970